Keyword: Vectura Group

GlaxoSmithKline just keeps racking up the victories in the generic Advair department, this time with a yearslong delay to Hikma's copy.

GSK already partners with Vectura on respiratory therapies, but the British pharma giant could be looking to take the relationship one step further.

Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.

The FDA has already nixed two generics of GSK's Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.

GlaxoSmithKline dodged yet another generic Advair bullet. Hikma and Vectura's knockoff was struck down at FDA Thursday, and an approval later this year is a long shot, the companies say.

Respiratory player Vectura can set aside its hopes of snagging a COPD indication for ICS/LABA med Flutiform--at least, for now.

Wannabe generic-Advair makers are confident they can shore up market share--without vastly undercutting one another on price.

There’s yet another respiratory drugmaker jumping on the “smart inhaler” bandwagon--and that’s the U.K.’s Vectura.